Open Payments

Boston Medical Center

Type
Teaching hospital
Where
Boston, MA
Medicare CCN
220031
Received
$7,049,386 in 501 records, 2022 ($1,002,282 general, $6,047,104 research)
Source
CMS Open Payments search ↗

By year

Program yearKindRecordsAmount
2022General payment75$1,002,282
2022Research payment426$6,047,104

By company

CompanyRecordsAmountYears
PFIZER INC.111$3,048,8282022
Merck Sharp & Dohme LLC17$875,0252022
Novartis Pharmaceuticals Corporation2$710,6622022
Gilead Sciences, Inc.2$520,0372022
G1 Therapeutics, Inc.13$387,1612022
Alexion Pharmaceuticals, Inc.5$384,1662022
VERTEX PHARMACEUTICALS INCORPORATED5$175,5732022
Janssen Research & Development, LLC17$146,4462022
Takeda Pharmaceuticals U.S.A., Inc.20$106,3872022
Myovant Sciences Inc.1$100,0002022
Regeneron Pharmaceuticals, Inc.2$57,3202022
KARL STORZ Endoscopy-America37$56,6422022
Indivior Inc.11$54,9632022
Celgene Corporation3$52,8352022
Novo Nordisk AS154$41,7252022
ABBVIE INC.9$40,9442022
Boston Scientific Corporation14$34,2712022
Intercept Pharmaceuticals, Inc.13$31,0842022
Hoffmann-La Roche Limited2$27,1762022
Laminate Medical Technologies inc.7$25,6212022
Agios Pharmaceuticals, Inc.3$23,1372022
Philips North America LLC6$20,3032022
AstraZeneca UK Limited1$19,5872022
Abbott Laboratories1$17,9872022
Route 92 Medical, Inc.1$16,8912022
TerSera Therapeutics LLC4$16,6422022
Organon Llc7$14,2672022
RedDress LTD1$8,1312022
Rigel Pharmaceuticals, Inc.2$8,1252022
Bayer Healthcare Pharmaceuticals Inc.1$6,4952022
E.R. Squibb & Sons, L.L.C.2$3,8002022
KLS-Martin L.P.1$3,7502022
Medline Industries LP1$2,6262022
Roche Diagnostics Corporation4$2,4952022
C. R. Bard, Inc. & Subsidiaries2$1,9822022
Acrotech Biopharma Inc.1$1,9112022
INSTYLLA, INC.1$1,3002022
GE HEALTHCARE9$1,0202022
GUERBET LLC1$9172022
Medical Device Business Services, Inc.3$6652022
NeurAxis, Inc.1$2892022
SANOFI US SERVICES INC.1$1212022
Olympus Corporation of the Americas1$502022
Merge Healthcare Incorporated1$152022

By nature of payment

NatureRecordsAmount
Research payment426$6,047,104
Grant8$881,889
Education37$56,642
Compensation for services other than consulting, including serving as faculty or as a speaker at a v11$54,963
Space rental or facility fees (teaching hospital only)1$4,500
Travel and Lodging2$2,114
Charitable Contribution10$1,281
Food and Beverage4$686
Debt forgiveness2$205

Records

DateCompanyAmountNatureFormProductStudyYear
2022-12-31Gilead Sciences, Inc.$513,139GrantCash or cash equivalent2022
2022-12-31Merck Sharp & Dohme LLC$78,889Research paymentIn-kind items and servicesGARDASIL 9 Biological, VACCINEAn Open-Label Clinical Trial Evaluating the Immunogenicity of the 9-valent 2-dose Vaccination Regimen over 6 months Amon2022
2022-12-31Merck Sharp & Dohme LLC$71,426Research paymentIn-kind items and servicesCharacterization of Systemic and Local Immune Responses to Chlamydia Antigens in Women to support Vaccine Antigen Select2022
2022-12-31Merck Sharp & Dohme LLC$25,285Research paymentIn-kind items and servicesGARDASIL 9 Biological, VACCINEAn Exploratory Open-Label Clinical Trial Evaluating the Immunogenicity of the 9vHPV Vaccination 2-dose Regimen over a Fo2022
2022-12-31Merck Sharp & Dohme LLC$21,354Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Phase 3 Double-blinded, Two-arm Study to Evaluate the Safety and Efficacy of Pembrolizumab MK-3475 versus Placebo as A2022
2022-12-31KARL STORZ Endoscopy-America$13,059EducationIn-kind items and services2022
2022-12-31Merck Sharp & Dohme LLC$11,642Research paymentIn-kind items and servicesLENVIMA Drug, ONCOLOGYA Phase 2, randomized, open-label three-arm clinical study to evaluate the safety and efficacy of lenvatinib E7080,MK-792022
2022-12-31RedDress LTD$8,131Research paymentCash or cash equivalentA Multi-Center, Prospective, Randomized, Controlled, Trial, Comparing the Safety and Efficacy of ActiGraft Pro to Standa2022
2022-12-31Merck Sharp & Dohme LLC$7,454Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Phase 3 Double-blinded, Two-arm Study to Evaluate the Safety and Efficacy of Pembrolizumab MK-3475 versus Placebo as A2022
2022-12-31KARL STORZ Endoscopy-America$6,408EducationIn-kind items and services2022
2022-12-31Merck Sharp & Dohme LLC$6,323Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Phase 3 Double-blinded, Two-arm Study to Evaluate the Safety and Efficacy of Pembrolizumab MK-3475 versus Placebo as A2022
2022-12-31Merck Sharp & Dohme LLC$4,360Research paymentIn-kind items and servicesLENVIMA Drug, ONCOLOGYA Phase 2, randomized, open-label three-arm clinical study to evaluate the safety and efficacy of lenvatinib E7080,MK-792022
2022-12-31KARL STORZ Endoscopy-America$3,638EducationIn-kind items and services2022
2022-12-31KARL STORZ Endoscopy-America$3,016EducationIn-kind items and services2022
2022-12-31Philips North America LLC$3,000Research paymentIn-kind items and services(6260) Ingenia 3 0T R5 Device, Medical DeviceWF-010536 / Evaluation of Image Quality of 3D Synthetic MRI in Children2022
2022-12-31KARL STORZ Endoscopy-America$2,994EducationIn-kind items and services2022
2022-12-31KARL STORZ Endoscopy-America$2,876EducationIn-kind items and services2022
2022-12-31KARL STORZ Endoscopy-America$2,773EducationIn-kind items and services2022
2022-12-31KARL STORZ Endoscopy-America$2,183EducationIn-kind items and services2022
2022-12-31KARL STORZ Endoscopy-America$2,073EducationIn-kind items and services2022
2022-12-31KARL STORZ Endoscopy-America$2,029EducationIn-kind items and services2022
2022-12-31KARL STORZ Endoscopy-America$2,022EducationIn-kind items and services2022
2022-12-31KARL STORZ Endoscopy-America$1,852EducationIn-kind items and services2022
2022-12-31KARL STORZ Endoscopy-America$1,660EducationIn-kind items and services2022
2022-12-31KARL STORZ Endoscopy-America$1,660EducationIn-kind items and services2022
2022-12-31KARL STORZ Endoscopy-America$1,547EducationIn-kind items and services2022
2022-12-31KARL STORZ Endoscopy-America$1,411EducationIn-kind items and services2022
2022-12-31Philips North America LLC$1,200Research paymentIn-kind items and services(6260) Ingenia 3 0T R5 Device, Medical DeviceWF-010536 / Evaluation of Image Quality of 3D Synthetic MRI in Children2022
2022-12-31ABBVIE INC.$1,000Research paymentIn-kind items and servicesSafety And Efficacy Study Of Intravenous (IV) Administration Of Elezanumab To Assess Change In Upper Extremity Motor Sco2022
2022-12-31KARL STORZ Endoscopy-America$872EducationIn-kind items and services2022
2022-12-31KARL STORZ Endoscopy-America$872EducationIn-kind items and services2022
2022-12-31KARL STORZ Endoscopy-America$814EducationIn-kind items and services2022
2022-12-31KARL STORZ Endoscopy-America$490EducationIn-kind items and services2022
2022-12-31KARL STORZ Endoscopy-America$361EducationIn-kind items and services2022
2022-12-31KARL STORZ Endoscopy-America$314EducationIn-kind items and services2022
2022-12-31KARL STORZ Endoscopy-America$314EducationIn-kind items and services2022
2022-12-31KARL STORZ Endoscopy-America$281EducationIn-kind items and services2022
2022-12-31KARL STORZ Endoscopy-America$189EducationIn-kind items and services2022
2022-12-31Merck Sharp & Dohme LLC$149Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg2022
2022-12-31KARL STORZ Endoscopy-America$125EducationIn-kind items and services2022
2022-12-31KARL STORZ Endoscopy-America$124EducationIn-kind items and services2022
2022-12-31KARL STORZ Endoscopy-America$101EducationIn-kind items and services2022
2022-12-31KARL STORZ Endoscopy-America$101EducationIn-kind items and services2022
2022-12-31KARL STORZ Endoscopy-America$101EducationIn-kind items and services2022
2022-12-31KARL STORZ Endoscopy-America$101EducationIn-kind items and services2022
2022-12-31KARL STORZ Endoscopy-America$65EducationIn-kind items and services2022
2022-12-31KARL STORZ Endoscopy-America$57EducationIn-kind items and services2022
2022-12-31KARL STORZ Endoscopy-America$57EducationIn-kind items and services2022
2022-12-31KARL STORZ Endoscopy-America$40EducationIn-kind items and services2022
2022-12-31KARL STORZ Endoscopy-America$24EducationIn-kind items and services2022
2022-12-31KARL STORZ Endoscopy-America$21EducationIn-kind items and services2022
2022-12-30C. R. Bard, Inc. & Subsidiaries$1,911Research paymentCash or cash equivalentArctic Sun 5000 Device, Medical SystemsINTREPID BMD11112022
2022-12-30PFIZER INC.$1,434Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIA2022
2022-12-28Novo Nordisk AS$23Research paymentIn-kind items and servicesOzempic Drug, DiabetesNN9535-43522022
2022-12-28Novo Nordisk AS$5Research paymentIn-kind items and servicesOzempic Drug, DiabetesNN9535-43522022
2022-12-27G1 Therapeutics, Inc.$12,403Research paymentCash or cash equivalentCOSELA Drug, ONCOLOGYA Phase 3, Randomized, Double-Blind Study of COSELA or Placebo in Patients Receiving First- or Second-Line Gemcitabine a2022
2022-12-22Boston Scientific Corporation$100Charitable ContributionCash or cash equivalent2022
2022-12-21PFIZER INC.$6,280Research paymentCash or cash equivalentPAXLOVID Drug, INFECTIOUS DISEASESA PHASE 23 INTERVENTIONAL SAFETY PHARMACOKINETICS AND EFFICACY OPENLABEL MULTICENTER SINGLEARM STUDY TO INVESTIGATE ORAL2022
2022-12-21Novo Nordisk AS$1,925Research paymentCash or cash equivalentOzempic Drug, DiabetesNN9535-43522022
2022-12-21TerSera Therapeutics LLC$1,404Research paymentCash or cash equivalentXermelo Drug, OncologyA Phase 2, Multicenter, open-label, safety and efficacy study of Xermelo (telotristat ethyl) plus first-line chemotherap2022
2022-12-20Janssen Research & Development, LLC$952Research paymentCash or cash equivalentDARZALEX Drug, OncologyRandomized Phase 3 Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide Bortezo2022
2022-12-20Boston Scientific Corporation$100Charitable ContributionCash or cash equivalent2022
2022-12-19PFIZER INC.$226,180Research paymentCash or cash equivalentSURVEILLANCE OF PNEUMOCOCCAL COLONIZATION IN CHILDREN LESS THAN 5 YEARS OF AGE AT BOSTON MEDICAL CENTER2022
2022-12-19Merck Sharp & Dohme LLC$5,149Research paymentCash or cash equivalentKEYTRUDA Biological, ONCOLOGYA Phase 3 Double-blinded, Two-arm Study to Evaluate the Safety and Efficacy of Pembrolizumab MK-3475 versus Placebo as A2022
2022-12-16PFIZER INC.$2,300Research paymentCash or cash equivalentPREVNAR 20 Biological, VACCINESA PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY IN2022
2022-12-16Organon Llc$1,460Research paymentCash or cash equivalent8415-0602022
2022-12-16PFIZER INC.$1,020Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESA PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT2022
2022-12-14PFIZER INC.$10,716Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESA MASTER PHASE 123 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BIVALENT BNT162B2 RNA BASED VAC2022
2022-12-14PFIZER INC.$4,734Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESPHASE 1 OPENLABEL DOSEFINDING STUDY TO EVALUATE SAFETY TOLERABILITY AND IMMUNOGENICITY AND PHASE 23 PLACEBOCONTROLLED OB2022
2022-12-12Boston Scientific Corporation$100Charitable ContributionCash or cash equivalent2022
2022-12-10PFIZER INC.$21,836Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED2022
2022-12-09PFIZER INC.$6,077Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESA PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT2022
2022-12-08Takeda Pharmaceuticals U.S.A., Inc.$516Research paymentCash or cash equivalentA PHASE-III, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, INTERNATIONAL, MULTICENTRE STUDY TO ASSESS EF2022
2022-12-08Novo Nordisk AS$23Research paymentIn-kind items and servicesOzempic Drug, DiabetesNN9535-43522022
2022-12-08Novo Nordisk AS$2Research paymentIn-kind items and servicesOzempic Drug, DiabetesNN9535-43522022
2022-12-07PFIZER INC.$11,880Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESPHASE 1 OPENLABEL DOSEFINDING STUDY TO EVALUATE SAFETY TOLERABILITY AND IMMUNOGENICITY AND PHASE 23 PLACEBOCONTROLLED OB2022
2022-12-07Merge Healthcare Incorporated$15Food and BeverageCash or cash equivalentSoftware Device, Medical Imaging2022
2022-12-06PFIZER INC.$6,000Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIA2022
2022-12-02Boston Scientific Corporation$100Charitable ContributionCash or cash equivalent2022
2022-12-01Regeneron Pharmaceuticals, Inc.$54,720Research paymentCash or cash equivalentA MASTER PROTOCOL ASSESSING THE SAFETY, TOLERABILITY, AND EFFICACY OF ANTI-SPIKE (S) SARS-COV-2 MONOCLONAL ANTIBODIES FO2022
2022-12-01Indivior Inc.$5,000Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentSUBLOCADE Drug, OUD2022
2022-12-01Indivior Inc.$4,963Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentSUBLOCADE Drug, OUD2022
2022-12-01PFIZER INC.$487Research paymentCash or cash equivalentPAXLOVID Drug, INFECTIOUS DISEASESA PHASE 23 INTERVENTIONAL SAFETY PHARMACOKINETICS AND EFFICACY OPENLABEL MULTICENTER SINGLEARM STUDY TO INVESTIGATE ORAL2022
2022-12-01Novo Nordisk AS$23Research paymentIn-kind items and servicesOzempic Drug, DiabetesNN9535-43522022
2022-12-01Novo Nordisk AS$2Research paymentIn-kind items and servicesOzempic Drug, DiabetesNN9535-43522022
2022-11-30Merck Sharp & Dohme LLC$26,273Research paymentCash or cash equivalentLENVIMA Drug, ONCOLOGYA Phase 2, randomized, open-label three-arm clinical study to evaluate the safety and efficacy of lenvatinib E7080,MK-792022
2022-11-30PFIZER INC.$12,239Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESA MASTER PHASE 123 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BIVALENT BNT162B2 RNA BASED VAC2022
2022-11-30Novo Nordisk AS$3,075Research paymentCash or cash equivalentOzempic Drug, DiabetesNN9535-43522022
2022-11-29Boston Scientific Corporation$154Charitable ContributionCash or cash equivalent2022
2022-11-23G1 Therapeutics, Inc.$16,471Research paymentCash or cash equivalentCOSELA Drug, ONCOLOGYA Phase 3, Randomized, Double-Blind Study of COSELA or Placebo in Patients Receiving First- or Second-Line Gemcitabine a2022
2022-11-23PFIZER INC.$7,976Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESA MASTER PHASE 123 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BIVALENT BNT162B2 RNA BASED VAC2022
2022-11-23Intercept Pharmaceuticals, Inc.$1,867Research paymentCash or cash equivalentOCALIVA Drug, Hepatology / GastroenterologyRandomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment (REGENERATE)2022
2022-11-22PFIZER INC.$18,230Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESA MASTER PHASE 123 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BIVALENT BNT162B2 RNA BASED VAC2022
2022-11-22Novo Nordisk AS$180Research paymentIn-kind items and servicesOzempic Drug, DiabetesNN9535-43522022
2022-11-22Novo Nordisk AS$180Research paymentIn-kind items and servicesOzempic Drug, DiabetesNN9535-43522022
2022-11-22Novo Nordisk AS$180Research paymentIn-kind items and servicesOzempic Drug, DiabetesNN9535-43522022
2022-11-22Novo Nordisk AS$180Research paymentIn-kind items and servicesOzempic Drug, DiabetesNN9535-43522022
2022-11-22Novo Nordisk AS$180Research paymentIn-kind items and servicesOzempic Drug, DiabetesNN9535-43522022
2022-11-22Novo Nordisk AS$180Research paymentIn-kind items and servicesOzempic Drug, DiabetesNN9535-43522022
2022-11-22Novo Nordisk AS$180Research paymentIn-kind items and servicesOzempic Drug, DiabetesNN9535-43522022
2022-11-22Novo Nordisk AS$180Research paymentIn-kind items and servicesOzempic Drug, DiabetesNN9535-43522022
2022-11-22Novo Nordisk AS$180Research paymentIn-kind items and servicesOzempic Drug, DiabetesNN9535-43522022
2022-11-22Novo Nordisk AS$180Research paymentIn-kind items and servicesOzempic Drug, DiabetesNN9535-43522022
2022-11-22Novo Nordisk AS$180Research paymentIn-kind items and servicesOzempic Drug, DiabetesNN9535-43522022
2022-11-22Novo Nordisk AS$180Research paymentIn-kind items and servicesOzempic Drug, DiabetesNN9535-43522022
2022-11-22Novo Nordisk AS$180Research paymentIn-kind items and servicesOzempic Drug, DiabetesNN9535-43522022
2022-11-22Novo Nordisk AS$180Research paymentIn-kind items and servicesOzempic Drug, DiabetesNN9535-43522022
2022-11-22Novo Nordisk AS$180Research paymentIn-kind items and servicesOzempic Drug, DiabetesNN9535-43522022
2022-11-22Novo Nordisk AS$180Research paymentIn-kind items and servicesOzempic Drug, DiabetesNN9535-43522022
2022-11-22Novo Nordisk AS$180Research paymentIn-kind items and servicesOzempic Drug, DiabetesNN9535-43522022
2022-11-22Novo Nordisk AS$180Research paymentIn-kind items and servicesOzempic Drug, DiabetesNN9535-43522022
2022-11-22Novo Nordisk AS$180Research paymentIn-kind items and servicesOzempic Drug, DiabetesNN9535-43522022
2022-11-22Novo Nordisk AS$180Research paymentIn-kind items and servicesOzempic Drug, DiabetesNN9535-43522022
2022-11-22Novo Nordisk AS$180Research paymentIn-kind items and servicesOzempic Drug, DiabetesNN9535-43522022
2022-11-22Novo Nordisk AS$180Research paymentIn-kind items and servicesOzempic Drug, DiabetesNN9535-43522022
2022-11-22Novo Nordisk AS$180Research paymentIn-kind items and servicesOzempic Drug, DiabetesNN9535-43522022
2022-11-22Novo Nordisk AS$180Research paymentIn-kind items and servicesOzempic Drug, DiabetesNN9535-43522022
2022-11-22Novo Nordisk AS$180Research paymentIn-kind items and servicesOzempic Drug, DiabetesNN9535-43522022
2022-11-21Janssen Research & Development, LLC$67,164Research paymentCash or cash equivalent2022
2022-11-18TerSera Therapeutics LLC$1,300Research paymentCash or cash equivalentXermelo Drug, OncologyA Phase 2, Multicenter, open-label, safety and efficacy study of Xermelo (telotristat ethyl) plus first-line chemotherap2022
2022-11-18TerSera Therapeutics LLC$1,300Research paymentCash or cash equivalentXermelo Drug, OncologyA Phase 2, Multicenter, open-label, safety and efficacy study of Xermelo (telotristat ethyl) plus first-line chemotherap2022
2022-11-18Medical Device Business Services, Inc.$275Research paymentCash or cash equivalentACTIS Device, Ortho-HipActis Total Hip System 2 Year Follow up2022
2022-11-16Philips North America LLC$11,505Research paymentCash or cash equivalent(9532) PD Other Device, Medical DeviceLFQ Phase II Study2022
2022-11-16PFIZER INC.$1,012Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESA PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT2022
2022-11-15PFIZER INC.$103,770Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESA MASTER PHASE 123 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BIVALENT BNT162B2 RNA BASED VAC2022
2022-11-15PFIZER INC.$15,820Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESPHASE 1 OPENLABEL DOSEFINDING STUDY TO EVALUATE SAFETY TOLERABILITY AND IMMUNOGENICITY AND PHASE 23 PLACEBOCONTROLLED OB2022
2022-11-08Janssen Research & Development, LLC$7,500Research paymentCash or cash equivalentAn Open label Phase 11b Study to Evaluate the Safety and Pharmacokinetics of JNJ73841937 Lazertinib a Third Generation E2022
2022-11-05PFIZER INC.$3,899Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIA2022
2022-11-04SANOFI US SERVICES INC.$121Charitable ContributionCash or cash equivalent2022
2022-11-03Novo Nordisk AS$23Research paymentIn-kind items and servicesOzempic Drug, DiabetesNN9535-43522022
2022-11-03Novo Nordisk AS$8Research paymentIn-kind items and servicesOzempic Drug, DiabetesNN9535-43522022
2022-11-02PFIZER INC.$62,074Research paymentCash or cash equivalentBIOTHERAPEUTICS TARGETING SLIT2ROBO2 SIGNALING PATHWAY TO TREAT PATIENTS WITH CHRONIC KIDNEY2022
2022-11-02G1 Therapeutics, Inc.$13,767Research paymentCash or cash equivalentCOSELA Drug, ONCOLOGYA Phase 3, Randomized, Double-Blind Study of COSELA or Placebo in Patients Receiving First- or Second-Line Gemcitabine a2022
2022-11-02TerSera Therapeutics LLC$12,637Research paymentCash or cash equivalentXermelo Drug, OncologyA Phase 2, Multicenter, open-label, safety and efficacy study of Xermelo (telotristat ethyl) plus first-line chemotherap2022
2022-11-01PFIZER INC.$1,940Research paymentCash or cash equivalentPAXLOVID Drug, INFECTIOUS DISEASESA PHASE 23 INTERVENTIONAL SAFETY PHARMACOKINETICS AND EFFICACY OPENLABEL MULTICENTER SINGLEARM STUDY TO INVESTIGATE ORAL2022
2022-10-31Merck Sharp & Dohme LLC$6,727Research paymentCash or cash equivalentCharacterization of Systemic and Local Immune Responses to Chlamydia Antigens in Women to support Vaccine Antigen Select2022
2022-10-31Janssen Research & Development, LLC$3,485Research paymentCash or cash equivalentDARZALEX Drug, OncologyRandomized Phase 3 Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide Bortezo2022
2022-10-26VERTEX PHARMACEUTICALS INCORPORATED$100,000GrantCash or cash equivalent2022
2022-10-26PFIZER INC.$35,414Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESA PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT2022
2022-10-26Agios Pharmaceuticals, Inc.$16,125Research paymentCash or cash equivalentPYRUKYND Drug, Genetically Defined DiseaseA Phase 2/3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Mita2022
2022-10-26Indivior Inc.$5,000Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentSUBLOCADE Drug, OUD2022
2022-10-26Agios Pharmaceuticals, Inc.$3,762Research paymentCash or cash equivalentPYRUKYND Drug, Genetically Defined DiseaseA Phase 2/3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Mita2022
2022-10-26Agios Pharmaceuticals, Inc.$3,250Research paymentCash or cash equivalentPYRUKYND Drug, Genetically Defined DiseaseA Phase 2/3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Mita2022
2022-10-25PFIZER INC.$3,190Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIA2022
2022-10-24Janssen Research & Development, LLC$11,459Research paymentCash or cash equivalentAn Open label Phase 11b Study to Evaluate the Safety and Pharmacokinetics of JNJ73841937 Lazertinib a Third Generation E2022
2022-10-21Novo Nordisk AS$1,810Research paymentCash or cash equivalentOzempic Drug, DiabetesNN9535-43522022
2022-10-21Organon Llc$1,616Research paymentCash or cash equivalentNEXPLANON Drug, ETONOGESTRELA Study to Assess Contraceptive Efficacy and Safety of Etonogestrel (ENG) Implant Beyond 3 Years of Use (MK-8415-060)2022
2022-10-14PFIZER INC.$12,814Research paymentCash or cash equivalentPAXLOVID Drug, INFECTIOUS DISEASESA PHASE 23 INTERVENTIONAL SAFETY PHARMACOKINETICS AND EFFICACY OPENLABEL MULTICENTER SINGLEARM STUDY TO INVESTIGATE ORAL2022
2022-10-12PFIZER INC.$1,350Research paymentCash or cash equivalentPREVNAR 20 Biological, VACCINESA PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY IN2022
2022-10-06PFIZER INC.$16,091Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESA PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT2022
2022-10-06ABBVIE INC.$9,509Research paymentCash or cash equivalentVENCLEXTA Drug, ONCOLOGYA Study of Venetoclax and Dexamethasone Compared With Pomalidomide and Dexamethasone in Participants With Relapsed or Re2022
2022-10-06PFIZER INC.$3,880Research paymentCash or cash equivalentPAXLOVID Drug, INFECTIOUS DISEASESA PHASE 23 INTERVENTIONAL SAFETY PHARMACOKINETICS AND EFFICACY OPENLABEL MULTICENTER SINGLEARM STUDY TO INVESTIGATE ORAL2022
2022-10-05G1 Therapeutics, Inc.$24,070Research paymentCash or cash equivalentCOSELA Drug, ONCOLOGYA Phase 3, Randomized, Double-Blind Study of COSELA or Placebo in Patients Receiving First- or Second-Line Gemcitabine a2022
2022-10-03NeurAxis, Inc.$289Food and BeverageCash or cash equivalent2022
2022-10-01PFIZER INC.$29,847Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESPHASE 1 OPENLABEL DOSEFINDING STUDY TO EVALUATE SAFETY TOLERABILITY AND IMMUNOGENICITY AND PHASE 23 PLACEBOCONTROLLED OB2022
2022-10-01PFIZER INC.$18,247Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESA PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT2022
2022-09-28Abbott Laboratories$17,987Research paymentCash or cash equivalentFREESTYLE LIBRE 14 DAY Device, Diabetes CareEVALUATION OF FLASH CONTINUOUS GLUCOSE MONITORING TO REDUCE HYPERGLYCEMIA IN PEOPLE WITH T2 DIABETES2022
2022-09-28Novo Nordisk AS$1,810Research paymentCash or cash equivalentOzempic Drug, DiabetesNN9535-43522022
2022-09-28Organon Llc$1,460Research paymentCash or cash equivalentNEXPLANON Drug, ETONOGESTRELA Study to Assess Contraceptive Efficacy and Safety of Etonogestrel (ENG) Implant Beyond 3 Years of Use (MK-8415-060)2022
2022-09-28C. R. Bard, Inc. & Subsidiaries$71Debt forgivenessIn-kind items and services2022
2022-09-27PFIZER INC.$5,324Research paymentCash or cash equivalentPAXLOVID Drug, INFECTIOUS DISEASESA PHASE 23 INTERVENTIONAL SAFETY PHARMACOKINETICS AND EFFICACY OPENLABEL MULTICENTER SINGLEARM STUDY TO INVESTIGATE ORAL2022
2022-09-27Novo Nordisk AS$23Research paymentIn-kind items and servicesOzempic Drug, DiabetesNN9535-43522022
2022-09-27Novo Nordisk AS$8Research paymentIn-kind items and servicesOzempic Drug, DiabetesNN9535-43522022
2022-09-26Regeneron Pharmaceuticals, Inc.$2,600Research paymentCash or cash equivalentA MASTER PROTOCOL ASSESSING THE SAFETY, TOLERABILITY, AND EFFICACY OF ANTI-SPIKE (S) SARS-COV-2 MONOCLONAL ANTIBODIES FO2022
2022-09-22PFIZER INC.$140,508Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESA PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC2022
2022-09-22PFIZER INC.$7,888Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIA2022
2022-09-21PFIZER INC.$6,756Research paymentCash or cash equivalentPAXLOVID Drug, INFECTIOUS DISEASESA PHASE 23 INTERVENTIONAL SAFETY PHARMACOKINETICS AND EFFICACY OPENLABEL MULTICENTER SINGLEARM STUDY TO INVESTIGATE ORAL2022
2022-09-15Intercept Pharmaceuticals, Inc.$158Research paymentCash or cash equivalentOCALIVA Drug, Hepatology / GastroenterologyRandomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment (REGENERATE)2022
2022-09-15Intercept Pharmaceuticals, Inc.$158Research paymentCash or cash equivalentOCALIVA Drug, Hepatology / GastroenterologyRandomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment (REGENERATE)2022
2022-09-14Indivior Inc.$5,000Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentSUBLOCADE Drug, OUD2022
2022-09-14Laminate Medical Technologies inc.$2,405Research paymentCash or cash equivalentVasQ External Support Device, BA Multi-center Prospective Study to Evaluate the Safety and Effectiveness of the VasQ External Support for Arteriovenous2022
2022-09-13Laminate Medical Technologies inc.$11,376Research paymentCash or cash equivalentVasQ External Support Device, BA Multi-center Prospective Study to Evaluate the Safety and Effectiveness of the VasQ External Support for Arteriovenous2022
2022-09-12Laminate Medical Technologies inc.$2,600Research paymentCash or cash equivalentVasQ External Support Device, BA Multi-center Prospective Study to Evaluate the Safety and Effectiveness of the VasQ External Support for Arteriovenous2022
2022-09-10PFIZER INC.$5,062Research paymentCash or cash equivalentPAXLOVID Drug, INFECTIOUS DISEASESA PHASE 23 INTERVENTIONAL SAFETY PHARMACOKINETICS AND EFFICACY OPENLABEL MULTICENTER SINGLEARM STUDY TO INVESTIGATE ORAL2022
2022-09-09Janssen Research & Development, LLC$10,539Research paymentCash or cash equivalentAn Open label Phase 11b Study to Evaluate the Safety and Pharmacokinetics of JNJ73841937 Lazertinib a Third Generation E2022
2022-09-09Takeda Pharmaceuticals U.S.A., Inc.$4,500Space rental or facility fees (teaching hospital only)Cash or cash equivalent2022
2022-09-06Janssen Research & Development, LLC$545Research paymentCash or cash equivalentDARZALEX Drug, OncologyRandomized Phase 3 Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide Bortezo2022
2022-09-02G1 Therapeutics, Inc.$37,111Research paymentCash or cash equivalentCOSELA Drug, ONCOLOGYA Phase 3, Randomized, Double-Blind Study of COSELA or Placebo in Patients Receiving First- or Second-Line Gemcitabine a2022
2022-09-02PFIZER INC.$17,974Research paymentCash or cash equivalentIBRANCE Drug, ONCOLOGYPALBOCICLIB AFTER CDK AND ENDOCRINE THERAPY PACEA RANDOMIZED PHASE II STUDY OF FULVESTRANT PALBOCICLIB AND AVELUMAB FOR 2022
2022-09-02PFIZER INC.$3,975Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIA2022
2022-09-02Novo Nordisk AS$23Research paymentIn-kind items and servicesOzempic Drug, DiabetesNN9535-43522022
2022-09-02Novo Nordisk AS$2Research paymentIn-kind items and servicesOzempic Drug, DiabetesNN9535-43522022
2022-08-25Philips North America LLC$1,911Research paymentCash or cash equivalent(9532) PD Other Device, Medical DeviceECS Study2022
2022-08-23PFIZER INC.$1,452Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESA PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT2022
2022-08-23PFIZER INC.$932Research paymentCash or cash equivalentPREVNAR 20 Biological, VACCINESA PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY IN2022
2022-08-22Novo Nordisk AS$2,692Research paymentCash or cash equivalentOzempic Drug, DiabetesNN9535-43522022
2022-08-17PFIZER INC.$13,259Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESA PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC2022
2022-08-17PFIZER INC.$13,180Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESPHASE 1 OPENLABEL DOSEFINDING STUDY TO EVALUATE SAFETY TOLERABILITY AND IMMUNOGENICITY AND PHASE 23 PLACEBOCONTROLLED OB2022
2022-08-17PFIZER INC.$1,001Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESA PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT2022
2022-08-16Medical Device Business Services, Inc.$50Research paymentCash or cash equivalentACTIS Device, Ortho-HipActis Total Hip System 2 Year Follow up2022
2022-08-11PFIZER INC.$6,027Research paymentCash or cash equivalentPAXLOVID Drug, INFECTIOUS DISEASESA PHASE 23 INTERVENTIONAL SAFETY PHARMACOKINETICS AND EFFICACY OPENLABEL MULTICENTER SINGLEARM STUDY TO INVESTIGATE ORAL2022
2022-08-10PFIZER INC.$2,313Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESPHASE 1 OPENLABEL DOSEFINDING STUDY TO EVALUATE SAFETY TOLERABILITY AND IMMUNOGENICITY AND PHASE 23 PLACEBOCONTROLLED OB2022
2022-08-05PFIZER INC.$3,258Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIA2022
2022-08-04PFIZER INC.$16,155Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESA PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT2022
2022-08-04PFIZER INC.$16,017Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESPHASE 1 OPENLABEL DOSEFINDING STUDY TO EVALUATE SAFETY TOLERABILITY AND IMMUNOGENICITY AND PHASE 23 PLACEBOCONTROLLED OB2022
2022-08-04ABBVIE INC.$2,853Research paymentCash or cash equivalentVENCLEXTA Drug, ONCOLOGYA Study of Venetoclax and Dexamethasone Compared With Pomalidomide and Dexamethasone in Participants With Relapsed or Re2022
2022-08-04Intercept Pharmaceuticals, Inc.$1,709Research paymentCash or cash equivalentOCALIVA Drug, Hepatology / GastroenterologyRandomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment (REGENERATE)2022
2022-08-03G1 Therapeutics, Inc.$22,074Research paymentCash or cash equivalentCOSELA Drug, ONCOLOGYA Phase 3, Randomized, Double-Blind Study of COSELA or Placebo in Patients Receiving First- or Second-Line Gemcitabine a2022
2022-08-03Indivior Inc.$5,000Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentSUBLOCADE Drug, OUD2022
2022-08-03Indivior Inc.$5,000Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentSUBLOCADE Drug, OUD2022

The latest 200 records of 501.

CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.

The area Census

Suffolk CountyBoston city

County outline, the place (blue), the tract (orange) and the ZIP center (dot).

In Boston, MA, county Suffolk County, MA, state Massachusetts; placed by its city name.

MeasurePlace (city or town)
Boston, MA
County
Suffolk County, MA
State
Massachusetts
Population B01003666,442785,1217,044,056
Population, 2020 census P1675,647797,9367,029,917
Median age B0100233.333.940.0
Under 18 B0100115.1%16.0%19.4%
65 and over B0100113.0%13.3%17.9%
Households B11001283,374327,1672,785,042
Foreign born B0500227.8%29.8%18.0%
Median household income B19013$97,344$95,631$103,960
Median family income B19113$116,436$112,072$131,675
Per capita income B19301$61,698$58,636$57,897
Poverty rate B1700116.6%16.2%10.0%
Unemployment rate B230256.1%6.3%5.2%
Civilian labor force B23025402,354468,6363,911,446
Mean commute (minutes) B0801330.330.929.1
Bachelor's degree or higher B1500354.9%50.6%47.3%
Housing units B25001310,625357,2903,030,406
Owner-occupied B2500335.7%36.5%62.5%
Renters B2500364.3%63.5%37.5%
Median home value B25077$731,700$705,800$562,100
Median gross rent B25064$2,147$2,129$1,762
White, not Hispanic B0300244.1%43.6%66.6%
Black B0300219.3%17.1%6.4%
Hispanic or Latino B0300219.3%23.2%13.3%
Asian B0300210.3%9.2%7.3%
American Indian and Alaska Native B030020.1%0.1%0.1%

Economy now FRED unemployment 4.3% in Sep 2026 (4.6% a year earlier); per capita personal income $98,700 in 2025, up 27% in five years (+2.3% after inflation); Unemployment rate: 3.8% in Sep 2016 to 4.3% in Sep 2026; low 3.0%, high 17.8% the state; Source: FRED, Federal Reserve Bank of St. Louis.

Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Boston, MA.

Comments

Anonymous: no account or email. Up to 2,000 characters, at most one link. Comments are checked automatically; some wait for review.